Clinical Trial Detail

NCT ID NCT01715285
Title A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

prostate cancer

Therapies

Abiraterone + Prednisone

Age Groups: senior adult

No variant requirements are available.